This record provides bibliographic details and links to the original research. An editorial study breakdown is not available.
What the researchers found
EVX-01 elicited long-lasting T-cell responses in all five patients with no severe adverse events.
Why it matters
This research highlights the potential of personalized immunotherapy in treating melanoma, a challenging cancer type. The findings support further exploration of neoantigen vaccines in cancer treatment.
How the study worked
The study involved an interim analysis of five patients receiving six administrations of the personalized vaccine, with tumor neoantigens identified using an AI platform.
What this study cannot tell us
The study is based on a small sample size and is an interim analysis, limiting the generalizability of the findings.
Read the original research
Personalized therapy with peptide-based neoantigen vaccine (EVX-01) including a novel adjuvant, CAF®09b, in patients with metastatic melanoma.
Oncoimmunology, 11(1), 2023255
Citation
Mørk, Sofie Kirial; Kadivar, Mohammad; Bol, Kalijn Fredrike; Draghi, Arianna; Westergaard, Marie Christine Wulff; Skadborg, Signe Koggersbøl; Overgaard, Nana; Sørensen, Anders Bundgård; Rasmussen, Ida Svahn; Andreasen, Lars Vibe; Yde, Christina Westmose; Trolle, Thomas; Garde, Christian; Friis-Nielsen, Jens; Nørgaard, Nis; Christensen, Dennis; Kringelum, Jens Vindahl; Donia, Marco; Hadrup, Sine Reker; Svane, Inge Marie. (2022). Personalized therapy with peptide-based neoantigen vaccine (EVX-01) including a novel adjuvant, CAF®09b, in patients with metastatic melanoma.. Oncoimmunology, 11(1), 2023255. https://doi.org/10.1080/2162402X.2021.2023255